Therapeutic application of stem cell technology toward the treatment of Parkinson's disease

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 2, 2013, Pages 171-175

  Nishimura, Kaneyasu ^a,b   Takahashi, Jun ^a,b  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Disease modeling; Dopaminergic neuron; Drug discovery; Parkinson's disease; Stem cell therapy

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; DISEASE MODEL; DOPAMINERGIC NERVE CELL; EMBRYONIC STEM CELL; HUMAN; IN VITRO STUDY; MESENCEPHALON; NERVE CELL DIFFERENTIATION; NONHUMAN; PARKINSON DISEASE; PATIENT SAFETY; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; DOPAMINERGIC NEURONS; EMBRYONIC STEM CELLS; HUMANS; MESENCEPHALON; PARKINSON DISEASE; PLURIPOTENT STEM CELLS; STEM CELLS;

EID: 84874046508     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00929     Document Type: Article

References (41)

1. Samii A, Nutt JG, Ransom BR Parkinson's disease. Lancet, 363, 1783-1793 (2004).
2. Nishimura K, Inoue T, Yoshimoto K., Taniguchi T, Kitamura Y, Agata K. Regeneration of dopaminergic neurons after 6-hydroxy-dopamine-induced lesion in planarian brain. J. neurochem., 119, 1217-1231 (2011).
3. Berg DA, Kirkham M, Wang H., Frisén J, Simon A. dopamine controls neurogenesis in the adult salamander midbrain in homeostasis and during regeneration of dopamine neurons. Cell Stem Cell, 8, 426-433 (2011).
4. Thomson JA, Itskovitz-Eldor J, Shapiro S.S., Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM Embryonic stem cell lines derived from human blastocysts. Science, 282, 1145-1147 (1998).
5. Takahashi K, Tanabe K, Ohnuki M., Narita M, Ichisaka T, Tomoda K., yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861-872 (2007).
6. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J., Jonsdottir GA, Ruotti V, Stewart R, Slukvin I.I., Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science, 318, 1917-1920 (2007).
7. Brundin P, Strecker RE, Lindvall O, Isacson O., Nilsson OG, Barbin G, Prochiantz A, Forni C., Nieoullon A, Widner H, Gage F.H., Björklund A. Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease. Ann. n. Y. Acad. Sci., 495 (1 cell and Tiss), 473-496 (1987).
8. Burbach JP, Smidt M P. Molecular programming of stem cells into mesodiencephalic dopaminergic neurons. trends neurosci., 29, 601-603 (2006).
9. Ye W, Shimamura K, Rubenstein J.L., Hynes MA, Rosenthal A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell, 93, 755-766 (1998).
10. Andersson E, Tryggvason U, Deng Q., Friling S, Alekseenko Z, Robert B., Perlmann T, Ericson J. Identification of intrinsic determinants of midbrain dopamine neurons. Cell, 124, 393-405 (2006).
11. Ferri AL, Lin W, Mavromatakis Y.E., Wang JC, Sasaki H, Whitsett JA, Ang SL Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development, 134, 2761-2769 (2007).
12. Nunes I, Tovmasian LT, Silva R.M., Burke RE, Goff SP Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. natl. Acad. Sci. U.S.A., 100, 4245-4250 (2003).
13. Saucedo-Cardenas O., Quintana-Hau JD, Le W.D., Smidt MP, Cox JJ, de Mayo F, Burbach JP, Conneely OM Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. natl. Acad. Sci. U.S.A., 95, 4013-4018 (1998).
14. Watanabe K, Kamiya D, Nishiyama A., Katayama T, Nozaki S, Kawasaki H., Watanabe Y, Mizuseki K, Sasai Y. directed differentiation of telencephalic precursors from embryonic stem cells. nat. neurosci., 8, 288-296 (2005).
15. Chambers SM, Fasano CA, Papapetrou E.P., Tomishima M., Sadelain M, Studer L. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAd signaling. nat. Biotechnol., 27, 275-280 (2009).
16. Morizane A, Doi D, Kikuchi T., Nishimura K, Takahashi J. Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J. neurosci. Res., 89, 117-126 (2011).
17. Kriks S, Shim JW, Piao J, Ganat Y.M., Wakeman DR, Xie Z, Carrillo-Reid L, Auyeung G, Antonacci C., Buch A, Yang L, Beal M.F., Surmeier DJ, Kordower JH, Tabar V, Studer L. dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. nature, 480, 547-551 (2011).
18. Kirkeby A, Grealish S, Wolf D.A., Nelander J., Wood J, Lundblad M, Lindvall O., Parmar M. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep., 1, 703-714 (2012).
19. Shimohama S, Sawada H, Kitamura Y., Taniguchi T. disease model: Parkinson's disease. trends Mol. Med., 9, 360-365 (2003).
20. Saiki H, Hayashi T, Takahashi R., Takahashi J. Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease. J. neurosci. Methods, 190, 198-204 (2010).
21. Takagi Y, Takahashi J, Saiki H., Morizane A, Hayashi T, Kishi Y., Fukuda H, Okamoto Y, Koyanagi M., Ideguchi M, Hayashi H, Imazato T, Kawasaki H, Suemori H, Omachi S, Iida H, Itoh N, Nakatsuji N, Sasai Y, Hashimoto N. dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J. Clin. Invest., 115, 102-109 (2005).
22. Doi D, Morizane A, Kikuchi T., Onoe H, Hayashi T, Kawasaki T., Motono M, Sasai Y, Saiki H., Gomi M, Yoshikawa T, Hayashi H, Shinoyama M, Refaat MM, Suemori H, Miyamoto S, Takahashi J. Prolonged maturation culture favors a reduction in the tumorigenicity and the dopaminergic function of human ESc-derived neural cells in a primate model of Parkinson's disease. Stem Cells, 30, 935-945 (2012).
23. Kikuchi T, Morizane A, Doi D., Onoe H, Hayashi T, Kawasaki T., Saiki H, Miyamoto S, Takahashi J. Survival of human induced pluripotent stem cell-derived midbrain dopaminergic neurons in the brain of a primate model of Parkinson's disease. J. Parkinson's Dis., 1, 395-412 (2011).
24. Okita K, Matsumura Y, Sato Y., Okada A, Morizane A, Okamoto S., Hong H, Nakagawa M, Tanabe K., Tezuka K, Shibata T, Kunisada T, Takahashi M, Takahashi J, Saji H, Yamanaka S. A more efficient method to generate integration-free human iPS cells. Nat. Methods, 8, 409-412 (2011).
25. Park IH, Arora N, Huo H., Maherali N, Ahfeldt T, Shimamura A., Lensch MW, Cowan C, Hochedlinger K, Daley GQ Disease-specific induced pluripotent stem cells. Cell, 134, 877-886 (2008).
26. Soldner F, Hockemeyer D, Beard C., Gao Q, Bell GW, Cook E.G., Hargus G., Blak A, Cooper O, Mitalipova M., Isacson O, Jaenisch R. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell, 136, 964-977 (2009).
27. Byers B, Cord B, Nguyen H.N., Schüle B, Fenno L., Lee PC, Deisseroth K, Langston JW, Pera R.R., Palmer TD. SNcA triplication Parkinson's patient's iPSc-derived dA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS ONE, 6, e26159 (2011).
28. Devine MJ, Ryten M, Vodicka P., Thomson AJ, Burdon T, Houlden H, Cavaleri F., Nagano M, Drummond NJ, Taanman J.W., Schapira AH, Gwinn K, Hardy J, Lewis PA, Kunath T. Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat. Commun., 2, 440 (2011).
29. Seibler P, Graziotto J, Jeong H., Simunovic F, Klein C, Krainc D. Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. J. neurosci., 31, 5970-5976 (2011).
30. Nguyen HN, Byers B, Cord B., Shcheglovitov A, Byrne J, Gujar P., Kee K, Schüle B, Dolmetsch R.E., Langston W., Palmer TD, Pera RR. LRRK2 mutant iPSc-derived dA neurons demonstrate increased susceptibility to oxidative stress. Cell Stem Cell, 8, 267-280 (2011).
31. Sánchez-Danés A, Richaud-Patin Y, Carballo-Carbajal I, Jiménez-Delgado S, Caig C, Mora S, Di Guglielmo C, Ezquerra M, Patel B, Giralt A, Canals JM, Memo M, Alberch J, López-Barneo J, Vila M, Cuervo AM, Tolosa E, Consiglio A, Raya A. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson's disease. EMBo Mol. Med., 4, 380-395 (2012).
32. Jiang H, Ren Y, Yuen E.Y., Zhong P., Ghaedi M, Hu Z, Azabdaftari G., Nakaso K, Yan Z, Feng J. Parkin controls dopamine utilization in human midbrain dopaminergic neurons derived from induced pluripotent stem cells. nat. Commun., 3, 668 (2012).
33. Imaizumi Y, Okada Y, Akamatsu W., Koike M, Kuzumaki N, Hayakawa H., Nihira T, Kobayashi T, Ohyama M., Sato S, Takanashi M, Funayama M, Hirayama A, Soga T, Hishiki T, Suematsu M, Yagi T, Ito D, Kosakai A, Hayashi K, Shouji M, Nakanishi A, Suzuki N, Mizuno Y, Mizushima N, Amagai M, Uchiyama Y, Mochizuki H, Hattori N, Okano H. Mitochondrial dysfunction associated with increased oxidative stress and alpha-synuclein accumulation in PARK2 iPSc-derived neurons and postmortem brain tissue. Mol. Brain, 5, 35 (2012).
34. Kahle PJ. α-Synucleinopathy models and human neuropathology: similarities and differences. Acta neuropathol., 115, 87-95 (2008).
35. Singleton AB, Farrer M, Johnson J., Singleton A, Hague S, Kachergus J., Hulihan M, Peuralinna T, Dutra A., Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. α-Synuclein locus triplication causes Parkinson's disease. Science, 302, 841 (2003).
36. Satake W, Nakabayashi Y, Mizuta I., Hirota Y, Ito C, Kubo M., Kawaguchi T, Tsunoda T, Watanabe M., Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. nat. Genet., 41, 1303-1307 (2009).
37. Hargus G, Cooper O, Deleidi M., Levy A, Lee K, Marlow E., Yow A, Soldner F, Hockemeyer D., Hallett PJ, Osborn T, Jaenisch R, Isacson O. differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc. natl. Acad. Sci. U.S.A., 107, 15921-15926 (2010).
38. Ebert AD, Svendsen CN Human stem cells and drug screening: opportunities and challenges. nat. Rev. Drug Discov., 9, 367-372 (2010).
39. Egawa N, Kitaoka S, Tsukita K., Naitoh M, Takahashi K, Yamamoto T., Adachi F, Kondo T, Okita K., Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H. Drug screening for AlS using patient-specific induced pluripotent stem cells. Sci. transl. Med., 4, 145ra104 (2012).
40. Chen G, Gulbranson DR, Hou Z, Bolin J.M., Ruotti V., Probasco MD, Smuga-Otto K, Howden SE, Diol N.R., Propson NE, Wagner R, Lee GO, Antosiewicz-Bourget J, Teng J.M., Thomson JA. Chemically defined conditions for human iPSC derivation and culture. nat. Methods, 8, 424-429 (2011).
41. Freed CR, Greene PE, Breeze R.E., Tsai WY, Dumouchel W, Kao R, Dillon S., Winfield H, Culver S, Trojanowski J.Q., Eidelberg D., Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. n. Engl. J. Med., 344, 710-719 (2001).